Ciprian Jauca

Managing Editor of the Cochrane Hypertension Group

[Therapeutics Initiative (TI) @Drug_Evidence]

🆕 TI Therapeutics Letter 153 🚨

Triple therapy for #COPD: Understanding evidence is complicated: https://t.co/nRJgVnQ9D7

Current evidence doesn't support first-line triple tx in treatment-naïve COPD patients, nor routinely adding ICS for people already using LAMA/LABA inhaler

[Therapeutics Initiative (TI) @Drug_Evidence]

TI Methods Speaker Series webinar: Evaluating study registration & result reporting of trials conducted in 🇨🇦

REGISTER NOW ➡️ https://t.co/mZMI0egIwk

Mohsen Alayche discusses his recent paper, which found significant deficiencies in Open Science, capturing global media interest

[Therapeutics Initiative (TI) @Drug_Evidence]

🎺 #ResearchMethods webinar recording!

#Preprints: Catalyzing Equity and Integrity in Scientific Discourse https://t.co/tFIjX9YHlG

Exploring how pre-prints foster transparency + accelerate scientific progress

Considering necessary safeguards to maintain research integrity

[Therapeutics Initiative (TI) @Drug_Evidence]

🎺 TOMORROW (8 May @ noon PDT)

#Deprescribing webinar: Antidepressant withdrawal effects & how to safely stop🛑

✅Maudsley approach to deprescribing #antidepressants
✅Distinguishing withdrawal effects
✅Hyperbolic tapering

Speaker: @markhoro
Register: https://t.co/SCRWc2k9Ra

[Therapeutics Initiative (TI) @Drug_Evidence]

7/ What should I tell my patients about #Paxlovid for new-onset #COVID19?

For most people with COVID-19, Paxlovid will:
✖️NOT make you feel better faster
✖️NOT lower your chance of dying or going to hospital

👉🏽Full Letter + patient materials: https://t.co/KzjGJFBOyV

#PatientEd

[Therapeutics Initiative (TI) @Drug_Evidence]

🧵How useful is #Paxlovid for #COVID19 in 2024?

1/ New clinical trials evidence shows nirmatrelvir-ritonavir (Paxlovid) has
relatively limited effectiveness for most people with new-onset COVID-19 infection

👉🏽 https://t.co/KzjGJFBOyV

#MedEd #COVID #prescribing #overtreatment

[Therapeutics Initiative (TI) @Drug_Evidence]

🎺TI Therapeutics Letter 149:
How useful is #Paxlovid in 2024?
https://t.co/KzjGJFCmot

In people at LOWER risk:
🤒Doesn't shorten symptoms
🏥Doesn't ↘️ risk of hospitalization or death

In people at HIGHER risk:
↘️reduces hospitalization w/ #COVID19 & risk of death

#MedEd

[André Picard @picardonhealth]

Who needs #Paxlovid now? New guidelines suggest only highest-risk groups should get #COVID19 drug. Recommendations for provincial drug plans feature narrower definition of who should qualify, by @LaurenPelley
https://t.co/fU96xh92TJ via @cbcnews

[Therapeutics Initiative (TI) @Drug_Evidence]

🆕#Deprescribing webinar: Antidepressant withdrawal effects & how to safely stop them🛑

✅Maudsley approach to deprescribing #antidepressants
✅Distinguishing withdrawal effects
✅Hyperbolic tapering

Speaker: @markhoro
Register: https://t.co/SCRWc2kHGI

#medsafety #MedEd

[Therapeutics Initiative (TI) @Drug_Evidence]

🆕UBC TI #ResearchMethods webinar recording 😍

Professor @StephenSenn's overview of the history of research synthesis: https://t.co/9cNkkMB40K

#EvidenceSynthesis #MetaAnalysis #ResearchSynthesis @rlmcelreath @_MiguelHernan

[Therapeutics Initiative (TI) @Drug_Evidence]

🆕Our latest #Deprescribing webinar recording is now available!

💊 Reassessment of drug therapies
🫱🏿‍🫲🏽 Approaches to patient-prescriber collaboration
⚠️ Signs+symptoms after medication changes

https://t.co/SPt73k2uYE

#MedEd #ptsafety #prescribing

[Ciprian Jauca @CiprianJauca]

Canadians need independent information and evaluation of drugs - Sign the Petition! https://t.co/dOc3du0YCY via @CdnChange

[Ciprian Jauca @CiprianJauca]

Stop the closure of the CPSBC Library - Sign the Petition! https://t.co/YWVnobOGUB via @CdnChange

[Therapeutics Initiative (TI) @Drug_Evidence]

🆕 TI #ResearchMethods webinar 😍

Professor Stephen Senn's overview of the history of #ResearchSynthesis

🗓️27 March @ Noon Pacific 🕛
👉🏽REGISTER: https://t.co/9cNkkMB40K

#EvidenceSynthesis #MetaAnalysis

[Therapeutics Initiative (TI) @Drug_Evidence]

🆕UBC TI Therapeutics Letter 1⃣4⃣6⃣:

#Apixaban is safer and more effective than rivaroxaban for non-valvular atrial fibrillation
👉🏽https://t.co/IB3bHe9i8u

#MedEd #medsafety #prescribing #DOACs #NVAF

[Therapeutics Initiative (TI) @Drug_Evidence]

🎺We are thrilled to welcome our newest TI member, Dr. Siyana Kurteva!🤩

Siyana is an epidemiologist focused on generating observational research using best practices to improve #prescribing and #medsafety issues

👉🏽https://t.co/zheOhVx7oM

#WelcomeSiyana

[Therapeutics Initiative (TI) @Drug_Evidence]

🆕 #ResearchMethods WEBINAR! 😍 📊 👨🏾‍🏫

How can we address overlap of primary studies in overviews? Find out at our 28 Feb Methods Speaker Series webinar 👇🏽

Speaker: Dr. Javier Bracchiglione @JBracchiglione
REGISTER here: https://t.co/nscNTsv4w3

#ResearchonResearch #Overviews

[Therapeutics Initiative (TI) @Drug_Evidence]

📢 Online WORKSHOP 📢
Intro to #MachineLearning in Python

Classification & clustering models:
✅Applications in machine learning
✅Training models for real-world data sets
✅Interpret + analyze results

🎙️Dr. Shayan Fahimi
🖊️Register: https://t.co/V8IdtUy1Un

#ResearchMethods

[Cochrane Hypertension @CochraneHTN]

🆕#HTN Protocol publication alert 🚨
#Riboflavin supplements for #BloodPressure lowering in adults

Our @CochraneLibrary review will assess the efficacy and safety of riboflavin supplements for lowering systolic and diastolic blood pressure:
https://t.co/z8CGxrflrW

[Therapeutics Initiative (TI) @Drug_Evidence]

🚨Calling all meta-analysts! 🚨

Our November 29 UBC TI Methods Speaker Series webinar looks at Likelihood Ratio #MetaAnalysis (LRMA)

Speaker: Dr. Colin Dormuth @ColinDormuth
Register: https://t.co/CiUgndSiTH

#ResearchMethods